Skip to main content

Lab drug cut chemical release in MS-like mouse tissue

By MS Buddy ·

Summarized from Neuropharmacology, Nov 2026 · PubMed. AI-generated summary. Not medical advice.

Lab study · healthy mice and mice with an MS-like disease

Research by Nicole Rosenwasser, Anna Pittaluga and 5 colleagues at the University of Genoa in Italy.

Can a lab drug reduce excess chemical release in MS-like mouse tissue?

Key Takeaway

In spinal cord tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve endings.

Two views of spinal cord nerve endings, with fewer chemical particles around the endings on the right.
Credibility
Interest
Share:1 min read

What They Found

Spinal cord tissue from mice with an MS-like disease showed signs of nerve covering damage. It also showed signs of increased immune activity. Nerve endings in that tissue released more of a chemical linked to nerve signaling than those from healthy mice. The lab drug DF2593A reduced this release in tissue from mice with the MS-like disease. In tissue from healthy mice, DF2593A and another drug also reduced chemical release triggered by immune activity.

Who Should Care and Why

This study used healthy mice and mice with an MS-like disease, not people. Researchers tested nerve endings taken from the mice's spinal cords. The findings may interest people following early research on nerve signaling in MS. The study found changes in mouse tissue with an MS-like disease. It did not test whether changing those signals affects MS symptoms.

Important Considerations

You should know these were tests on mouse tissue, not a treatment study in people. The abstract does not state how many mice were studied. It does not show whether DF2593A improves symptoms or prevents nerve damage.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Neuropharmacology by et al.. Reproduced from the PubMed record.

Complement releases glutamate from the spinal cord glutamatergic synaptosomes through mechanisms involving amino-acid transporters (EAATs) and G protein coupled receptors (GPCRs), as suggested by the efficiency of the EAAT blocker dl-t-BOA and of entrapped Pertussis toxin (PTx) to half its releasing activity. The GPCR-mediated component involves C5aR1s since the C5aR1 non-competitive negative allosteric modulator DF2593A and the orthosteric antagonist W54011 concentration-dependently prevent the complement-evoked release of preloaded [3H]D-aspartate. Antagonism, however, emerged only after the prolonged exposure of synaptosomes to these ligands, suggesting a multiple-phase model of receptor antagonism. Consistent with the involvement of this receptor, spinal cord synaptosomal lysates showed C5aR1 immunostaining corresponding to a dimeric assembly of the protein. We next examined mice suffering from the experimental autoimmune encephalomyelitis (EAE), at the acute stage of the disease (21 ± 1 days post immunization). Spinal cord homogenates from these mice show decreased MOG immunopositivity, suggestive of diffuse demyelination, but increased GFAP, vimentin, CD11b and CD45 staining, predictive of ongoing astrocytosis, microgliosis and infiltration of lymphocytes. These signs were paralleled by the overaccumulation of C1q, C3 and C5 components and increased C5aR1 staining, but conserved GLT1 one, in synaptosomal lysates. Lastly, the complement-evoked [3H]D-Aspartate overflow from spinal cord synaptosomes was amplified when compared to controls, but still significantly reduced by DF2593A. These findings prove the existence of presynaptic release-regulating DF2593A-sensitive C5aR1s in spinal cord glutamatergic terminals, opening the road to therapeutic application of C5aR1 modulators to control symptoms associated with altered synaptic transmission during multiple sclerosis.

Categories

Early Research

Explore more research

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Two cut-paper nerve shapes with interrupted wraps, one surrounded by fewer rust-colored clusters than the other.
Experimental drug eased MS-like disease signs in mice

11/17/2026

An experimental drug eased nerve-related problems and reduced inflammation in mice with an MS-like d

Read More
Soft gray-blue layers with scattered rust-colored flecks and gently fragmenting edges on an off-white background.
Review explores cell death in MS and other diseases

11/17/2026

A review explores iron-driven cell death in MS and other diseases involving immune attacks on the bo

Read More
Stem cells beside a nerve fiber with gaps in its myelin covering and a short section of newly forming myelin.
MS study: Metformin-treated cells aided repair in mice

11/16/2026

In mice with damaged nerve coverings, fat-derived stem cells treated with metformin improved repair.

Read More
Two navy brain silhouettes with matching fold patterns sit side by side, loosely connected by a thread on cream.
Inherited brain structure patterns linked to MS risk

11/17/2026

Genetic and brain scan data linked inherited brain structure patterns to MS risk. Researchers also f

Read More
Navy nerve-like lines meet at a central junction, with gaps in their ochre protective sleeves.
MS tissue and mice show damage in a brain vision hub

11/17/2026

Donated MS brain tissue showed damage in a vision hub. Mouse findings linked local immune cell activ

Read More
Muted blue and clay ribbons curve across an off-white background, wrapped in soft layers of varying thickness.
Planned MS study will test scans to track worsening

11/16/2026

A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.